Fundraising Fox
DermBiont
Boston, US · Founded 2016 · Delaware corporation · 13 employees on LinkedIn · 9 known investors
Find your way into DermBiont
Sign up to see every warm intro you have to DermBiont
- Paths you didn't know you had: your email and LinkedIn already hold routes to the DermBiont team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
Founders & leadership
DermBiont was founded in 2016 by Robert Brucker.
RB
Robert BruckerCo-founder and Chief Scientific Officer2015–2025Robert Brucker is an executive officer at DermBiont with over 15 years of experience in scientific leadership and business development across startup and academic settings. He has led research and development initiatives in biotherapy, including advancement of drug candidates DBI-001 and DBI-002 through Phase 2 clinical trials.
NE
MD
Max DawsonExecutive AdvisorMax Dawson held executive and scientific roles across biotechnology companies including Vertex Pharmaceuticals, Merck Serono, Dyax, Adagene, and PellePharm, and previously served as Chief Operating Officer of DermBiont. He holds an MBA from Babson College's F.W. Olin Graduate School of Business and an undergraduate degree from Bates College.
Board
WR
JL
Jennifer LeeBoard director
DY
SB
Steven BastaBoard director
Investors · 9
Civilization Ventures Management, Llclisted by Civilization Ventures Management, LlcTiburon · $1M – $10M
How we know: Civilization Ventures Management, Llc's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Joyance Partnerslisted by Joyance PartnersBerlin
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
Olive Tree Capitallisted by Olive Tree CapitalBoston
How we know: Olive Tree Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Toba Capitallisted by Toba CapitalLos Angeles · $1M – $10M
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Valia Ventureslisted by Valia VenturesLondon · $50K – $50M
How we know: Valia Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Ataraxia VCreportedSan Francisco · $50K – $1M
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
Newpath PartnersinferredBoston · $50K – $10Mvia Daniel Yadegar · board
How we know: board seat on SEC Form D · Not right? Tell us
Pivotal Life SciencesreportedSan Francisco
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$114.2M disclosed across 10 rounds · 2019–2023
▶$32.7MraisedNov 2024 · 72 investors · BiotechnologyRule 506(b)
▶$32.7MraisedNov 2024 · 72 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel YadegarDirector
- Steven BastaDirector
- Karl R. BeutnerExecutive Officer, Director
- Nichola EliovitsExecutive Officer, Director
- Max DawsonExecutive Officer
- Wilder RamseyDirector
- Offering amount
- $45.3M
- Amount sold
- $32.7M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.7MraisedMar 2023 · 69 investors · BiotechnologyRule 506(b)
▶$4.7MraisedMar 2023 · 69 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karl R. BeutnerExecutive Officer, Director
- Wilder RamseyDirector
- Max DawsonExecutive Officer
- Steven BastaDirector
- Jennifer LeeDirector
- Nichola EliovitsExecutive Officer, Director
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedSep 2022 · 11 investors · BiotechnologyRule 506(b)
▶$2.5MraisedSep 2022 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven BastaDirector
- Wilder RamseyDirector
- Karl R BeutnerExecutive Officer, Director
- Jennifer LeeDirector
- Max DawsonExecutive Officer
- Nichola EliovitsExecutive Officer, Director
- Amount sold
- $2.5M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$830.3KraisedJan 2022 · 10 investors · BiotechnologyRule 506(b)
▶$830.3KraisedJan 2022 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Max DawsonExecutive Officer
- Nichola EliovitsExecutive Officer, Director
- Jennifer LeeDirector
- Karl R. BeutnerExecutive Officer, Director
- Ramsey WilderDirector
- Steven BastaDirector
- Offering amount
- $830.3K
- Amount sold
- $830.3K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$28.8MraisedDec 2021 · 42 investors · BiotechnologyRule 506(b)
▶$28.8MraisedDec 2021 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wilder RamseyDirector
- Nichola EliovitsExecutive Officer
- Steven BastaDirector
- Max DawsonExecutive Officer
- Jennifer LeeDirector
- Karl R. BeutnerExecutive Officer, Director
- Offering amount
- $39.5M
- Amount sold
- $28.8M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.2MraisedAug 2021 · 9 investors · BiotechnologyRule 506(b)
▶$19.2MraisedAug 2021 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven BastaDirector
- Jennifer LeeDirector
- Wilder RamseyDirector
- Karl R. BeutnerExecutive Officer, Director
- Robert BruckerExecutive Officer
- Nichola EliovitsExecutive Officer, Director
- Offering amount
- $19.2M
- Amount sold
- $19.2M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$6.6MraisedFeb 2021 · 19 investors · BiotechnologyRule 506(b)
▶$6.6MraisedFeb 2021 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wilder RamseyDirector
- Steven BastaDirector
- Nichola EliovitsExecutive Officer, Director
- Robert BruckerExecutive Officer
- Karl R. BeutnerExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $6.6M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$7.2MraisedOct 2020 · 19 investors · BiotechnologyRule 506(b)
▶$7.2MraisedOct 2020 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wilder RamseyDirector
- Robert BruckerExecutive Officer
- Nichola EliovitsExecutive Officer, Director
- Steven BastaDirector
- Karl R. BeutnerExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $7.2M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as DermBiont.
Frequently asked questions
- What does DermBiont do?
- DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
- Who founded DermBiont?
- DermBiont was founded by Robert Brucker in 2016.
- Who are DermBiont's investors?
- DermBiont's investors include Civilization Ventures Management, Llc, Joyance Partners, Olive Tree Capital, Start Capital, Toba Capital, Valia Ventures, Ataraxia VC, Newpath Partners and 1 more.
- How much funding has DermBiont raised?
- DermBiont has disclosed $114.2M raised across 10 rounds.
- Where is DermBiont headquartered?
- DermBiont is headquartered in Boston, US.